Summary One of the objectives of the intro­duction of the DRG system was to motivate service providers to increase efficiency. For the most part this has been successful per case flat-rate reimbursement has led to a change in policy on the part of hospitals. In order for a hospital to operate eco­nomically, service costs must be kept below the DRG-related compensation. Now that hospitals are no longer able to recover their service costs from the GKV (health care system) on a cost-price basis, but instead have to operate within the constraints of the uniform case-related lump-sum remuneration scheme, numerous institutions are under enormous pressure to reduce costs. The fixed case-related lump-sum remuneration system has thus made a direct comparison of their economical status possible. Une­cono­mical hospitals or clinics are now threatened by closure or takeover. In order to cover the cost of provid­ing a service, the necessary procedures/methods must now be evaluated not merely from a medical, but also from an economic point of view. Pharma­ceutical companies developing inno­vative products are therefore increasingly facing the challenge of explaining the use of a new product in terms of its economic impact on the hospital. In the present publication, the effects of Sugammadex a new product employed in anaesthesia to reverse neuromuscular blockade on in-hospital processes are described, and suggestions made for their eva­l­uation. The substance and its novel mechanism of action are first described, and the effects of its use on hospital processes then discussed. Finally, various possibilities on how to evaluate the eco­no­mic aspects of these process changes are present­ed and discuss­ed.